Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Feb 17, 2015
NEWARK, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen and Company 35th Annual Health Care Conference in Boston. Revance management is scheduled to present on Tuesday, March 3, 2015 at 8:40 am ET. Interested parties can access the l...
Feb 12, 2015
NEWARK, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that the Company will release fourth quarter and full year 2014 financial results on Monday, March 2, 2015 after t...
Jan 12, 2015
Specifies Milestones for Botulinum Toxin Product Candidates, Topical RT001 and Injectable RT002, for Aesthetic and Therapeutic IndicationsUpdates 2014 Financial Guidance NEWARK, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the u...
Jan 8, 2015
RT002 Achieved Median Duration of 7 Months Phase 2 Active Comparator Study Underway NEWARK, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, today announced publication in the peer re...
Jan 5, 2015
NEWARK, Calif., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, today announced initiation of the BELMONT trial, a Phase 2, Randomized, Double-Blind, DosE Ranging, Active and PLacebo Controlled, ...
Dec 18, 2014
NEWARK, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:^NBI), which will become effectiv...
Nov 20, 2014
NEWARK, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the 26th Annual Piper Jaffray Healthcare Conference. Revance manageme...
Nov 12, 2014
- Confirmation of Plans to Initiate Phase 2 Active Comparator Study for RT002 in 2014 -- Updated Full Year 2014 Financial Guidance - NEWARK, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today r...
Nov 4, 2014
NEWARK, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona. Reva...
Oct 29, 2014
NEWARK, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will release third quarter 2014 financial results on Wednesday, November 12, 2014 after the close of market. Re...
Page: FirstPrevious ...
10
... NextLast
= add release to Briefcase
Shareholder Tools